BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Alterome Therapeutics, Inc.
Verastem, Inc.
Astellas Pharma Inc
Tizona Therapeutics, Inc
Genentech, Inc.
University of California, San Diego
University of Chicago
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
BioAtla, Inc.
M.D. Anderson Cancer Center
AVEO Pharmaceuticals, Inc.
National Cancer Institute, Naples
Eye & ENT Hospital of Fudan University
Hanmi Pharmaceutical Company Limited
Massachusetts General Hospital
Amgen
Groupe Oncologie Radiotherapie Tete et Cou
Fox Chase Cancer Center
UNICANCER
NKGen Biotech, Inc.
M.D. Anderson Cancer Center
Peking University Cancer Hospital & Institute
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
UNC Lineberger Comprehensive Cancer Center
NYU Langone Health
Eli Lilly and Company
Oslo University Hospital
University of Pittsburgh
Array BioPharma
GERCOR - Multidisciplinary Oncology Cooperative Group
Fox Chase Cancer Center
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Eli Lilly and Company
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Dana-Farber Cancer Institute
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Ludwig-Maximilians - University of Munich
Merck KGaA, Darmstadt, Germany
EMD Serono
M.D. Anderson Cancer Center
University of Southampton
National Cancer Institute, France
Fudan University